Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (211-220 of 539) with videos related to

Pageof 54
Sort By:
Cancer Letters|October 15, 2013
Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulationFengjuan Fan, Giovanni Tonon, Muhammad Hasan Bashari, et al.
Experimental Hematology|November 13, 2012
Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myelomaIsabelle Herth, Mathias Witzens-Harig, Philipp Beckhove, et al.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Blood Cancer Journal|March 10, 2018
A systematic classification of death causes in multiple myelomaElias K Mai, Eva-Maria Haas, Stephan Lücke, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 26, 2023
Application of an artificial intelligence-based tool in [<sup>18</sup>F]FDG PET/CT for the assessment of bone marrow involvement in multiple myelomaChristos Sachpekidis, Olof Enqvist, Johannes Ulén, et al.
Plos One|December 31, 2013
Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaMartin Bøgsted, Anders E Bilgrau, Christopher P Wardell, et al.
Anti-Cancer Drugs|October 1, 2004
Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphomaJana Schlenzka, Thomas M Moehler, Sergey M Kipriyanov, et al.
Cytotherapy|November 26, 2009
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II studyStefan Fruehauf, Marlon Romano Veldwijk, Timon Seeger, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Pageof 54

Showing results (211-220 of 539) with videos related to

Sort By:
Pageof 54
Cancer Letters|October 15, 2013
Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulationFengjuan Fan, Giovanni Tonon, Muhammad Hasan Bashari, et al.
Experimental Hematology|November 13, 2012
Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myelomaIsabelle Herth, Mathias Witzens-Harig, Philipp Beckhove, et al.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
Blood|June 4, 2016
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up studyTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Blood Cancer Journal|March 10, 2018
A systematic classification of death causes in multiple myelomaElias K Mai, Eva-Maria Haas, Stephan Lücke, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 26, 2023
Application of an artificial intelligence-based tool in [<sup>18</sup>F]FDG PET/CT for the assessment of bone marrow involvement in multiple myelomaChristos Sachpekidis, Olof Enqvist, Johannes Ulén, et al.
Plos One|December 31, 2013
Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaMartin Bøgsted, Anders E Bilgrau, Christopher P Wardell, et al.
Anti-Cancer Drugs|October 1, 2004
Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphomaJana Schlenzka, Thomas M Moehler, Sergey M Kipriyanov, et al.
Cytotherapy|November 26, 2009
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II studyStefan Fruehauf, Marlon Romano Veldwijk, Timon Seeger, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Pageof 54